“How Do the USPTO and the EPO Approaches Differ – A Comparison,” MITTEILUNGEN DER DEUTSCHEN PATENTANWÄLTE, July/August 2022 Issue, Köllner & Partner mbB, Patentanwälte, Frankfurt am Main, Germany, August 10,…

American National v. Sleep Number Corporation, No. 2021-1030 (July 25, 2022) (nonprecedential); Patent No(s). 5,904,172; WO96/13947; 5,044,029 Key point(s): Under a substantial evidence standard, a reasonable fact finder could have…

Tris Pharma, Inc. v. Actavis Laboratories FL, Inc., No. 2021-1495 (July 7, 2022) (nonprecedential); Patent No(s). 8,465,765; 8,563,033; 8,778,390 Key point(s): • A hypothetical, aspirational disclosure in prior art may…

Novartis Pharmaceuticals Corp. v. Accord Healthcare, Inc. , No. 21-1070 (Jun. 21, 2022) (precedential) (2- 1); Patent No(s). 9,187,405 Key point(s): • For a negative claim limitation, the specification must…

In re Kiely, No. 2022-1076 (June 8, 2022) (nonprecedential); Patent Application No. 11/634,624 Key point(s): • A proper Markush claim incorporates a closed list of specified alternative limitations and the…

University of Massachusetts et al. v. L’Oréal S.A., No. 2021-1969 (June 13, 2022) (precedential) (3-0); Patent No(s). 6,423,327 & 6,645,513 Key point(s): • If the patentee believes the patent examiner’s…

Google LLC, v. IPA Technologies Inc., No. 2021-1179, (May 19, 2022) (precedential) (3-0); U.S. Patent Nos. 6,851,115 (’115) and 7,069,560 (’560) Key point(s): A complete Duncan Analysis is required to…

In re ZTE Corp., No. 2022-122 (May 5, 2022) (nonprecedential) Key point(s): • Arguments should be addressed in the body of a brief; arguments incorporated in a footnote are not…

ClearOne, Inc. v. Shure Acquisition Holdings, Inc., No. 2021-1517 (June 1, 2022) (precedential) (3-0); Patent No. 9,565,493 Key point(s): • Just because a claim term is susceptible to more than…

Nichia v. Document Security Systems, Nos. 2020-2261, 2020-2287 (April 26, 2022) (nonprecedential); Patent No(s). 7,524,087 Key point(s): A showing that a claim limitation is disclosed in the prior art, in…

Almirall, LLC v. Amneal Pharmaceuticals LLC, No. 2020-2331, (March 14, 2022) (precedential) (3-0); Patent No. 9,517,219 Key point  The presumption of obviousness based on overlapping ranges applies even when…

Travel Sentry, Inc. v. Tropp., No. 2021-1908, (February 14, 2022) (non-precedential); Patent Nos. 7,021,537 & 7,036,728 Key point • To preserve patent eligibility arguments for appeal, patent owner must have…